<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620290</url>
  </required_header>
  <id_info>
    <org_study_id>4877</org_study_id>
    <nct_id>NCT05620290</nct_id>
  </id_info>
  <brief_title>MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma</brief_title>
  <official_title>MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terry Fox Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to examine the safety profile and therapeutic efficacy of&#xD;
      MRI-guided focused ultrasound microbubble therapy and radiotherapy in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The approach uses relatively low-power ultrasound, operating with lower power levels than&#xD;
      high intensity focused ultrasound and ultrasound-based hyperthermia techniques, delivered on&#xD;
      the Sonalleve platform. The tumour will be sonicated before the radiation to enhance the&#xD;
      effect of therapy. The technique is spatially targeted and stimulates microbubbles using&#xD;
      low-power ultrasonic fields in the tumour location only. the primary aim of this research is&#xD;
      to evaluate the safety profile of MRI-guided ultrasound stimulated microbubble treatment and&#xD;
      radiation in patients with malignant melanoma. The secondary aim is to evaluate tumour&#xD;
      (primary and/or metastasis) response to MRI-guided ultrasound stimulated microbubble&#xD;
      treatment and radiation, as measured radiologically within the treated regions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2022</start_date>
  <completion_date type="Anticipated">June 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of toxicity and adverse events, scored on the National Cancer Institute Common Toxicity Criteria (NCI CTCAE 4.03)</measure>
    <time_frame>90 days</time_frame>
    <description>The patient will be assessed by a physician investigator and clinical research assistant (CRA) on the MRI-guided focused ultrasound + microbubble (MRgFUS + MB) treatment date and within follow up period of 90 days after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiological response</measure>
    <time_frame>2 years</time_frame>
    <description>The secondary aim is to evaluate tumour (primary and/or metastasis) response to MRgFUS + MB and radiation, which will be evaluated by tumour volume change.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Malignant Melanoma patients undergoing MRI-guided ultrasound-stimulated microbubble treatment plus radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Definity</intervention_name>
    <description>Stimulation of Definity microbubbles using Sonalleve device within tumour vasculature</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sonalleve Focused Ultrasound Device</intervention_name>
    <description>Sonalleve Focused Ultrasound Device</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  All biopsy-confirmed malignant melanoma of the skin, including metastatic lesions.&#xD;
&#xD;
          -  Stage I-IV malignant melanoma, per AJCC guidelines (8th Edition).&#xD;
&#xD;
          -  Patient referred for palliative radiotherapy/ standard radiotherapy/ neoadjuvant&#xD;
             radiotherapy/SBRT/ hypofractionation.&#xD;
&#xD;
          -  Patient on immunotherapy.&#xD;
&#xD;
          -  Able to understand and give informed consent.&#xD;
&#xD;
          -  Weight &lt;140kg&#xD;
&#xD;
          -  Target lesion visible by non-contrast MRI.&#xD;
&#xD;
          -  Target lesion accessible for MRg-FU procedure.&#xD;
&#xD;
          -  Able to communicate sensation during MRg-FU treatment.&#xD;
&#xD;
          -  Creatinine within normal institutional limits or creatinine clearance &gt;60 mL/min/1.73&#xD;
             m2 for patients with creatinine levels above the institutional upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women may not participate due to the embryotoxic effects of&#xD;
             protocol treatment. Women/ men of reproductive potential may not participate unless&#xD;
             they have agreed to use an effective contraceptive method.&#xD;
&#xD;
          -  Unable to have contrast-enhanced MRI scan - the standard of care criteria&#xD;
&#xD;
          -  Target lesion involves the skin surface causing ulceration, bleeding or discharge&#xD;
&#xD;
          -  Severe cardiovascular, neurological, renal or hematological chronic disease&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) Performance Status ≥ 3. Unable to tolerate&#xD;
             required stationary position during treatment&#xD;
&#xD;
          -  Cardiac disease or unstable hemodynamics, including myocardial infarction within six&#xD;
             months, unstable angina, congestive heart failure, ejection fraction &lt; 50%, cardiac&#xD;
             shunts, cardiac arrhythmia and cardiac pacemaker.&#xD;
&#xD;
          -  Contraindication to perflutren including subjects with a family or personal history of&#xD;
             QT prolongation or taking concomitant medications known to cause QTc prolongation like&#xD;
             cisapride, erythromycin, tricyclic antidepressants, Class IA and III antiarrhythmic&#xD;
             agents and some antipsychotics like haloperidol, droperidol, quetiapine, thioridazine,&#xD;
             ziprasidone.&#xD;
&#xD;
          -  Severe hypertension (diastolic BP &gt; 100 mmHg)&#xD;
&#xD;
          -  History of bleeding disorder, coagulopathy&#xD;
&#xD;
          -  Severely impaired renal function with estimated glomerular filtration rate &lt;&#xD;
             30ml/min/1.73m2 and/or on dialysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Gregory Czarnota, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Gregory Czarnota, MD, Ph.D.</last_name>
    <phone>(416) 480-6128</phone>
    <email>Gregory.Czarnota@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory J Czarnota, MD, PhD</last_name>
      <phone>(416) 480-6128</phone>
      <email>gregory.czarnota@sunnybrook.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>May 17, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Focused ultrasound</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Microbubbles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

